In detail, we identified through a combined structure and ligand-based virtual screening compound 645656—already known in the literature for its antibacterial activity [106]—as a potential CDK-1 and PARP-1 inhibitor, acting with a dual-target inhibition mechanism, as a potential effective monotherapy in BC. Here, PARP1 is linked to breast cancer.